TY - JOUR
T1 - NT-proAtrial Natriuretic Peptide as a possible biomarker of cardiopulmonary involvement in sarcoidosis
AU - Magrì, Damiano
AU - Agostoni, Piergiuseppe
AU - Ricotta, Agnese
AU - Pisani, Lara
AU - Cauti, Filippo Maria
AU - Onofri, Alessandro
AU - Bruno, Pierdonato
AU - Ricci, Alberto
AU - Volpe, Massimo
AU - Marchitti, Simona
AU - Mariotta, Salvatore
AU - Rubattu, Speranza
PY - 2013/4
Y1 - 2013/4
N2 - Background: Lung diffusion for carbon monoxide (DLCO) has been shown to associate with the risk of pulmonary arterial hypertension development and, most likely, with right ventricular (RV) myocardial dysfunction in sarcoidosis patients. Besides its known role as a marker of left ventricular dysfunction, experimental evidence suggests a role of NT-proAtrial Natriuretic Peptide (NT-proANP) also in modulating pulmonary circulation. We therefore investigated possible relationships between NT-proANP, lung diffusion impairment and RV dysfunction. Methods: Thirty-two pulmonary sarcoidosis outpatients and eighteen volunteers underwent full clinical assessment, including full lung function tests and Doppler echocardiography integrated with tissue Doppler imaging (TDI) study. Resting circulating NT-proBNP and NT-proANP plasma levels were also determined. Results: NT-proANP and RV-myocardial performance index (RV-MPI) were significantly higher in those patients with the greatest DL CO impairment, whereas no differences were found for NT-proBNP values. At multivariable analysis, only DLCO (β: - 0.496; standard error: 3.38; p = 0.000) and RV-MPI (β: 0.373; standard error: 6.56; p = 0.031) remained significantly associated with NT-proANP levels. Conclusions: Our finding may support a key role of NT-proANP in the complex mechanisms underlying modulation of lung function. An early increase in pulmonary vascular resistance may stimulate NT-proANP increase, thus explaining its association with signs of early RV myocardial dysfunction. This hypothesis warrants further confirmation.
AB - Background: Lung diffusion for carbon monoxide (DLCO) has been shown to associate with the risk of pulmonary arterial hypertension development and, most likely, with right ventricular (RV) myocardial dysfunction in sarcoidosis patients. Besides its known role as a marker of left ventricular dysfunction, experimental evidence suggests a role of NT-proAtrial Natriuretic Peptide (NT-proANP) also in modulating pulmonary circulation. We therefore investigated possible relationships between NT-proANP, lung diffusion impairment and RV dysfunction. Methods: Thirty-two pulmonary sarcoidosis outpatients and eighteen volunteers underwent full clinical assessment, including full lung function tests and Doppler echocardiography integrated with tissue Doppler imaging (TDI) study. Resting circulating NT-proBNP and NT-proANP plasma levels were also determined. Results: NT-proANP and RV-myocardial performance index (RV-MPI) were significantly higher in those patients with the greatest DL CO impairment, whereas no differences were found for NT-proBNP values. At multivariable analysis, only DLCO (β: - 0.496; standard error: 3.38; p = 0.000) and RV-MPI (β: 0.373; standard error: 6.56; p = 0.031) remained significantly associated with NT-proANP levels. Conclusions: Our finding may support a key role of NT-proANP in the complex mechanisms underlying modulation of lung function. An early increase in pulmonary vascular resistance may stimulate NT-proANP increase, thus explaining its association with signs of early RV myocardial dysfunction. This hypothesis warrants further confirmation.
KW - Atrial natriuretic peptide
KW - Lung diffusion capacity
KW - Myocardial dysfunction
KW - Pulmonary sarcoidosis
KW - Tissue Doppler imaging
UR - http://www.scopus.com/inward/record.url?scp=84875210788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875210788&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2012.12.010
DO - 10.1016/j.ejim.2012.12.010
M3 - Article
C2 - 23294508
AN - SCOPUS:84875210788
SN - 0953-6205
VL - 24
SP - 278
EP - 284
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
IS - 3
ER -